DISCLAIMER & IMPORTANT NOTICES

• Nature of Report: This forensic accounting analysis is based exclusively on publicly available financial statements, regulatory filings, earnings call transcripts, and supporting financial data as of Q3 FY26 (Jan 2026). This is NOT an audit, and does NOT constitute professional accounting or investment advice.
• Data Limitations: Forensic analysis is constrained by public disclosure. Non-disclosure does not prove existence of issues, but absence of expected disclosures is itself a governance concern. Subsidiary operations remain largely opaque due to limited consolidated reporting requirements in Indian standards.
• Management Guidance Accuracy: Management's historical guidance track record shows 80%+ accuracy on revenue and EBITDA margin targets. However, recent discrepancies on OCF, working capital days, and capex funding sources indicate either forecasting challenges or communication gaps. Users should demand management clarification on specific guidance misses before accepting forward guidance at face value.
• Accounting Standards Context: This analysis applies Ind-AS (Indian Accounting Standards) interpretation. Subsidiary consolidation requirements under Ind-AS 110 may be less stringent than US GAAP or IFRS for certain disclosure items. The lack of detailed subsidiary disclosures may be compliant with local standards but is suboptimal for investor protection.
• Cash Flow Analysis Caveat: Operating cash flow is significantly impacted by working capital seasonality in chemical industry. The FY25 negative OCF despite positive PAT is unusual but not impossible in a high-growth inventory-dependent business. However, FY24's negative OCF combined with FY25 suggests structural cash conversion issues, not just seasonality.
• Subsidiary Governance Risk: Eight unaudited subsidiaries in seven countries represents material governance risk. While not necessarily indicating fraud, the absence of individual audits and consolidated disclosures prevents external verification of subsidiary financial health. Management should be required to provide: (a) individual subsidiary financials, (b) purpose and intercompany relationships, (c) guarantees or contingent liabilities, (d) forex exposures by entity.
• Capex Execution Risk: The Rs 460 crore capex plan targets 5x+ asset turnover on new capacity. This is achievable for specialty chemicals but requires: (1) sustained revenue growth of 15-20% CAGR, (2) no major customer losses, (3) price realization maintenance despite capacity additions, (4) operational excellence in new plant ramp-up. Management should provide quarterly capex progress and capacity utilization tracking.
• Related-Party Transaction Risk: The complete absence of RPT disclosures despite having 8 subsidiaries is the single largest governance red flag. Even "nil" disclosures would be preferable. Until management provides detailed subsidiary RPT schedules, investor confidence in arm's-length pricing and fair dealing remains compromised.
• Not a Substitute for Professional Advice: This analysis is educational and analytical in nature. Investment decisions should only be made after consulting with qualified financial advisors, conducting independent due diligence, and receiving satisfactory management responses to the governance and disclosure gaps highlighted herein.
• Limitation of Forensic Scope: Forensic accounting relies on data analysis and pattern recognition. This analysis does NOT include: (a) interviews with management or auditors, (b) site visits or physical asset verification, (c) customer/supplier confirmation, (d) detailed ledger testing, (e) internal control evaluation. Professional forensic engagements would require these additional procedures.